Quintana Francisco J, VanHook Annalisa M
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Web Editor, Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005, USA.
Sci Signal. 2016 Jun 21;9(433):c15. doi: 10.1126/scisignal.aag2900.
This Podcast features an interview with Francisco Quintana, senior author of a Research Article that appears in the 21 June 2016 issue of Science Signaling, about a nanoparticle-based potential treatment strategy for type 1 diabetes (T1D). T1D is an autoimmune disease in which the immune system attacks the insulin-secreting β cells of the pancreas. Strategies that induce immune tolerance to pancreatic β cells would be effective treatments for T1D. Yeste et al coated gold nanoparticles with a molecule that induces immune tolerance and a β cell antigen that is commonly targeted by autoimmune T cells in T1D. When administered to mice that are genetically predisposed to spontaneously develop T1D, the nanoparticles suppressed the development of disease, reduced the activity of autoimmune T cells, and promoted the activity of regulatory T cells that suppress the autoimmune response. In addition to being translated into the clinic for treating T1D, this strategy could be adapted to restore immune tolerance in other diseases of autoimmunity by replacing the β cell antigen with other self-antigens.Listen to Podcast.
本期播客对弗朗西斯科·金塔纳进行了采访,他是发表于2016年6月21日《科学信号》杂志上一篇研究论文的资深作者,该论文介绍了一种基于纳米颗粒的1型糖尿病(T1D)潜在治疗策略。T1D是一种自身免疫性疾病,免疫系统会攻击胰腺中分泌胰岛素的β细胞。诱导对胰腺β细胞产生免疫耐受的策略将是治疗T1D的有效方法。耶斯特等人用一种可诱导免疫耐受的分子和一种在T1D中通常被自身免疫性T细胞靶向的β细胞抗原包裹金纳米颗粒。当将这些纳米颗粒给予具有自发发展为T1D遗传倾向的小鼠时,它们抑制了疾病的发展,降低了自身免疫性T细胞的活性,并促进了抑制自身免疫反应的调节性T细胞的活性。除了转化到临床用于治疗T1D外,通过用其他自身抗原替代β细胞抗原,该策略还可适用于恢复其他自身免疫性疾病中的免疫耐受。收听播客。